New insights into the pathology of pulmonary hypertension: Implication of the miR-210/ISCU1/2/Fe-S axis

Haiyang Tang, Ramon J. Ayon, Jason Yuan

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Elevated pulmonary arterial pressure in patients with pulmonary hypertension (PH) is mainly caused by increased pulmonary vascular resistance (PVR), due primarily to sustained pulmonary vasoconstriction and excessive pulmonary vascular remodeling. According to the current classification, PH has been classified into five categories based on etiology (Simonneau et al,). Among them, group 1 or pulmonary arterial hypertension (PAH) is a rare but progressive and deadly disease affecting ~1-10 per 1 million people. Despite expanding treatment options to ameliorate patients' symptoms, PAH remains a devastating disease with a poor long-term prognosis.

Original languageEnglish (US)
Pages (from-to)689-691
Number of pages3
JournalEMBO Molecular Medicine
Volume7
Issue number6
DOIs
StatePublished - Jun 1 2015

Fingerprint

Pulmonary Hypertension
Pathology
Lung
Vasoconstriction
Vascular Resistance
Arterial Pressure
Therapeutics

ASJC Scopus subject areas

  • Molecular Medicine

Cite this

New insights into the pathology of pulmonary hypertension : Implication of the miR-210/ISCU1/2/Fe-S axis. / Tang, Haiyang; Ayon, Ramon J.; Yuan, Jason.

In: EMBO Molecular Medicine, Vol. 7, No. 6, 01.06.2015, p. 689-691.

Research output: Contribution to journalArticle

@article{6cbd1be47df94a59acb0c51c339f7187,
title = "New insights into the pathology of pulmonary hypertension: Implication of the miR-210/ISCU1/2/Fe-S axis",
abstract = "Elevated pulmonary arterial pressure in patients with pulmonary hypertension (PH) is mainly caused by increased pulmonary vascular resistance (PVR), due primarily to sustained pulmonary vasoconstriction and excessive pulmonary vascular remodeling. According to the current classification, PH has been classified into five categories based on etiology (Simonneau et al,). Among them, group 1 or pulmonary arterial hypertension (PAH) is a rare but progressive and deadly disease affecting ~1-10 per 1 million people. Despite expanding treatment options to ameliorate patients' symptoms, PAH remains a devastating disease with a poor long-term prognosis.",
author = "Haiyang Tang and Ayon, {Ramon J.} and Jason Yuan",
year = "2015",
month = "6",
day = "1",
doi = "10.15252/emmm.201505160",
language = "English (US)",
volume = "7",
pages = "689--691",
journal = "EMBO Molecular Medicine",
issn = "1757-4676",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - New insights into the pathology of pulmonary hypertension

T2 - Implication of the miR-210/ISCU1/2/Fe-S axis

AU - Tang, Haiyang

AU - Ayon, Ramon J.

AU - Yuan, Jason

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Elevated pulmonary arterial pressure in patients with pulmonary hypertension (PH) is mainly caused by increased pulmonary vascular resistance (PVR), due primarily to sustained pulmonary vasoconstriction and excessive pulmonary vascular remodeling. According to the current classification, PH has been classified into five categories based on etiology (Simonneau et al,). Among them, group 1 or pulmonary arterial hypertension (PAH) is a rare but progressive and deadly disease affecting ~1-10 per 1 million people. Despite expanding treatment options to ameliorate patients' symptoms, PAH remains a devastating disease with a poor long-term prognosis.

AB - Elevated pulmonary arterial pressure in patients with pulmonary hypertension (PH) is mainly caused by increased pulmonary vascular resistance (PVR), due primarily to sustained pulmonary vasoconstriction and excessive pulmonary vascular remodeling. According to the current classification, PH has been classified into five categories based on etiology (Simonneau et al,). Among them, group 1 or pulmonary arterial hypertension (PAH) is a rare but progressive and deadly disease affecting ~1-10 per 1 million people. Despite expanding treatment options to ameliorate patients' symptoms, PAH remains a devastating disease with a poor long-term prognosis.

UR - http://www.scopus.com/inward/record.url?scp=84930179938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930179938&partnerID=8YFLogxK

U2 - 10.15252/emmm.201505160

DO - 10.15252/emmm.201505160

M3 - Article

C2 - 25851536

AN - SCOPUS:84930179938

VL - 7

SP - 689

EP - 691

JO - EMBO Molecular Medicine

JF - EMBO Molecular Medicine

SN - 1757-4676

IS - 6

ER -